RxDoctor Payments Data

Chelsey Miller, APRN

Family · Missoula, MTNPI 1225546070

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,467 of the $3,453 with a category attached, or 71.4%. 7 manufacturers reported payments, led by AbbVie at 48.3% of the total. Among family clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,453in general payments, 2019–2025

Across 106 payments — averaging $32.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$1K
  • Biogen$334
  • Bristol Myers Squibb$153
  • TG Therapeutics, Inc.$144
  • Biohaven Pharmaceuticals, Inc.$17
  • plus $13 from 1 others

What the payments were for

  • Consulting fees$1504%
  • Travel & lodging$83724%
  • Food & beverage$2,46771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,453 in reported general payments places this provider in the 95th percentile of 481 family providers in Montana.

See all family providers in Montana

Medicare billing

Part B allowed, 2024
$126,401
Medicare patients
327
Services billed
10,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone13$182,535
InbrijaLevodopa11$25,457
Carbidopa-LevodopaCarbidopa/Levodopa654$25,406
Emgality PenGalcanezumab-Gnlm25$20,138
Nurtec OdtRimegepant Sulfate11$11,408
UbrelvyUbrogepant11$10,753
Ajovy SyringeFremanezumab-Vfrm13$9,257
Carbidopa-Levodopa ErCarbidopa/Levodopa208$8,057
FingolimodFingolimod Hcl12$5,886
Entacapone36$4,790
RytaryCarbidopa/Levodopa13$4,347
Levetiracetam163$4,263
Gabapentin226$3,881
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone13$2,756
Memantine Hcl58$2,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$1,669$10,75311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 family providers in Montana.

Other family in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →